ArticleFrontiers in cellular and infection microbiology2022
Molecular characterization of NDM-1-producing carbapenem-resistant
Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- A New Challenge of Antibiotic-Resistant Bacteria: Carbapenem-ResistantMicroorganisms · 2026Review
- Co-occurrence ofFrontiers in cellular and infection microbiology · 2026Article
- Characterization and transmission dynamics of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae isolated from eight teaching hospitals in Guangdong province, China (2022-2024).BMC microbiology · 2025Article
- The clinical impact and dissemination of carbapenemase-producingMicrobiology spectrum · 2025Article
- Emergence and characterization of IncFII/IncR plasmids with multiple 5,692 bp-Frontiers in microbiology · 2025Article
- Molecular epidemiology of carbapenem-resistantPeerJ · 2025Article
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaAnnals of clinical microbiology and antimicrobials · 2024Article
- Carbapenem-ResistantInfection and drug resistance · 2024Article
- Genomic and clinical characteristics of carbapenem-resistantFrontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of this study was to clarify the molecular characterization of NDM-1-producing carbapenem-resistant Methods: Antimicrobial susceptibility and resistance genes were analyzed. Epidemiological relationship was analyzed by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST). Conjugation experiments were performed to determine the transferability of plasmids. Whole-genome sequencing (WGS) of strains was implemented, and the genetic environment of the Results: A total of 10 Conclusions: We first report a nosocomial outbreak of NDM-1-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.